Answers are grounded in this paper and cite their sources.
Spatially resolved transcriptomics (SRT) represents a major technological advance following single-cell RNA sequencing. By profiling gene expression while preserving tissue architecture, SRT addresses a central limitation of bulk transcriptomics and dissociation-based single-cell sequencing: the loss of positional information. This capability is particularly relevant to the cardiovascular system, whose physiological function and disease progression are shaped by regional anatomy, mechanical stress, vascular niches, immune infiltration, extracellular-matrix remodeling and metabolic adaptation. In this review, we summarize the principles, strengths and limitations of mainstream imaging-based and sequencing-based SRT technologies. We then synthesize cardiovascular applications across atherosclerosis, myocardial infarction, cardiac development, heart failure, cardiomyopathies and cardiac aging. We use spatial disease units (SDUs) as an integrative framework rather than an entirely new spatial entity. An SDU is a disease-linked, spatially delineable tissue unit that couples coherent cell states and molecular programs with coordinated microenvironmental interactions and a local pathological phenotype. We emphasize explicit identification criteria and the need for reproducibility, orthogonal support and translational testing. Finally, we discuss technical bottlenecks and a prospective path toward spatial biomarkers and niche-directed interventions. SRT provides a framework for examining cardiovascular disease as a spatially organized biological process. Its translational potential will depend on reproducible SDU identification, orthogonal validation and conversion of spatial findings into clinically feasible biomarkers or intervention strategies.
No takes yet. Share an insight, caveat, or question.
Quan et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: